RivaHR, YoonT, HendricksAJ, et al.Dupilumab for chronic hand eczema: A systematic review and meta-analysis. Dermatitis. 2024. Published online November 6; doi: 10.1089/derm.2024.0186
2.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. Published 2021 Mar 29; doi: 10.1136/bmj.n71
3.
AhnE, KangH. Concepts and emerging issues of network meta-analysis. Korean J Anesthesiol. 2021; 74(5):371–382; doi: 10.4097/kja.21358
OosterhavenJAF, VoorbergAN, RomeijnGLE, et al.Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. J Dermatol. 2019; 46(8):680–685; doi: 10.1111/1346-8138.14982
6.
LeeN, ChipalkattiN, ZancanaroP, et al.A retrospective review of dupilumab for hand dermatitis. Dermatology. 2019; 235(3):187–188; doi: 10.1159/000496481
7.
WaldmanRA, DeWaneME, SloanB, et al.Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients. J Am Acad Dermatol. 2020; 82(5):1251–1252; doi: 10.1016/j.jaad.2019.12.053
8.
VoorbergAN, RomeijnGLE, de Bruin-WellerMS, et al.The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry. Contact Dermatitis. 2022; 87(2):185–191; doi: 10.1111/cod.14104
9.
VoorbergAN, KamphuisE, ChristoffersWA, et al.Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: A randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023; 189(4):e24–e26; doi: 10.1093/bjd/ljad482. [published correction appears in Br J Dermatol. 2024 Jun 20;191(1):e1; doi: 10.1093/bjd/ljae157]. Br J Dermatol. 2023;189(4):400–409; doi: 10.1093/bjd/ljad156
10.
SimpsonEL, SilverbergJI, WormM, et al.Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024; 90(6):1190–1199; doi:10.1016/j.jaad.2023.12.066
